WHO WE ARE Long Island Bioscience Hub

LIBH_16

The Center for Biotechnology (CFB), a New York State Center for Advanced Technology, in collaboration with Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory and the Feinstein Institute for Medical Research, and with additional support provided by the National Institutes of Health REACH initiative (Research Evaluation and Commercialization Hub), Research Foundation for SUNY, and Empire State Development, has formed the Long Island Bioscience Hub.

About the LIBH

The Long Island Bioscience Hub (LIBH) aims to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

The development of these technologies is supported by several funding mechanisms as well as a comprehensive suite of technology commercialization services that will help faculty innovators move their academic innovations into the commercial sector via a start-up company, licensing opportunity, and/or a strategic partnership. The Hub focuses its resources on four specific areas:

  1. Expanding existing infrastructure to foster, prioritize, and commercialize innovations across partner institutions
  2. Implementing translational research initiatives that will accelerate development and create a pipeline of “commercial-ready” innovations
  3. Recruiting a regional talent pool of experienced Bio-Entrepreneurs in Residence (BEIRs) to facilitate early-stage company formation
  4. Educating faculty, post-docs, and graduate students about entrepreneurship and commercialization in the life sciences, and establishing a formal mentor network.

Funding Opportunities

  • Feasibility Award
  • Proof of Concept Award

The LIBH’s two-tiered technology development initiative collectively contributes to a pipeline of commercially promising biomedical technologies. The latest Request for Proposals has been released with a submission due date of December 1st, 2016, 11:59 PM EST. Proposals submitted after the due date will not be considered. All proposals must be uploaded through the submission portal.

Click here for a PDF outlining the full funding program overview and proposal guidelines. Note – a six-month interim progress report and annual report are required for every REACH funded project. You will find the template for the progress report and additional materials necessary for application below.

Download Funding Program Documents:

Funded Projects

November 2016 Awards: 

  • Profiling the human immune system with machine learning algorithms and bioinformatics software – Dr. Gurinder  Atwal,Cold Spring Harbor Laboratory (Feasibility)
  • REACH: The MELD computer method for discovery – Dr. Ken Dill, Stony Brook University (Proof of Concept)
  • REACH: Development of small molecule inhibitors for PLD6 as therapeutics for triple negative breast cancer – Dr. Michael Frohman, Stony Brook University (Feasibility)
  • REACH: Automation of Photoplethysmographic Screening for Coarctation of the Aorta and Patent Ductus Arteriosus – Dr. Robert I. Koppel, Feinstein Institute for Medical Research, Northwell Health (Feasibility)
  • REACH: Asymmetric Dual-Screen Active Matrix Flat Panel X-ray Imager – Dr. Anthony Lubinsky, Stony Brook University (Feasibility)
  • Mitigation of OA Induced Inflammation and Pain by Non-invasive Dynamic Array Ultrasound Generated Fluid Flow in Joints – Dr. Yi-Xian Qin, Stony Brook University (Feasibility)
  • REACH: Targeted Anti-Thrombotic Drug Delivery Using Engineered DNA Nano-Carriers – Dr. Oren Rotman, Stony Brook University (Feasibility)
  • REACH: Novel Radiotracers to Image Infection in Humans using Positron Emission Tomography – Dr. Peter Tonge, Stony Brook University (Feasibility)
  • REACH: Carbon-based nanoparticle delivery of nucleic acid expressing anti-amyloidogenic myelin basic protein (MBP) peptide to neurons to test feasibility of a novel approach to Alzheimer’s therapy – Dr. William Van Nostrand, Stony Brook University (Feasibility)
  • Targeting treatment-refractory myelodysplastic syndrome with small molecule drugs modulating novel hematopoietic progenitor self-renewal pathways – Dr. Lingbo Zhang, Cold Spring Harbor Laboratory (Feasibility)

Feasibility Awards

  • Therapeutic for Clostridium difficile antibiotic-associated diarrheal disease – Dr. James Bliska
  • Device for rapid, simple and highly parallel single-cell processing – Dr. Eric Brouzes
  • Targeting Pathogenic Viral Infections with First-In-Class Viral Budding Inhibitors – Dr. Carol Carter
  • Developing a small molecule drug to treat systemic C. albicans infections – Dr. Nicholas Carpino
  • Next generation hedgehog inhibitor for invasive basal cell carcinoma – Dr. Jiang Chen
  • Development of Small Molecule Inhibitors for PLD6 as Therapeutics for Triple Negative Breast Cancer – Dr. Michael Frohman
  • A Novel Strategy for Recombinant AAV Vector Production for Gene Therapy – Dr. Patrick Hearing
  • Novel miR-129 Based Therapeutics for Colon Cancer – Dr. Jingfang Ju
  • Fast Hybrid Approach For Determination of Structure of Therapeutic Protein Complexes – Dr. Dima Kosakov
  • A tandem-integration-based multi-barcode method for high-throughput combinatorial screening – Dr. Sasha Levy
  • Enhancement of Protein Yields Using Mechanical Signals: Augmenting Biotech Production to Reduce Drug Costs – Dr. Gabriel Pagnotti
  • Non-invasive Acoustic Radiation Force Therapy for OA Induced Pain and Cartilage Regeneration – Dr. Yixian Qin
  • Novel CAIX Targeted Combination Inhibitor/PET tracer to treat patients with solid tumors – Dr. Peter Smith-Jones
  • Substrate-Assisted Tethered Inhibitors of LigA to Treat MDR Gonorrhea – Dr. Peter Tonge
  • LDL as Biomarker for Childhood Tuberculosis (TB) – Dr. Xinxin Yang

Proof of Concept Awards

  • A New Standard of Care for Implant Bed Preparation Utilizing an Innovative Drill Bit Technology – Dr. Marcus Abboud
  • Orthovoltage X-Ray Minibeams: Brain Tumor Therapy with Tissue-sparing Incident Beams – Dr. Avraham Dilmanian
  • NEW‐HARP: A Highly Sensitive Avalanche Selenium Detector for Time‐of‐Flight (TOF) Positron Emission Tomography (PET) – Dr. Amirhossein Goldan
  • fMRI Dynamic Phantom for Improved Detection of Resting-State Brain Networks – Dr. Lilianne Mujica-Parodi
  • Development of SMASH technology as a next-gen sequencing diagnostic for congenital heart disease – Dr. Michael Ronemus
  • Azasteroids for Combination Anti-TB Therapy – Dr. Nicole Sampson
  • A Novel Glioblastoma Drug – Oncolytic Virus PV1-Mono-Cre – Dr. Eckard Wimmer

Support for Commercialization & Entrepreneurial Activities

Understanding the issues surrounding commercialization of academic innovations is critical if the goal is to impact human health. To support faculty, post-doctoral associate, and graduate student understanding of these issues, and to streamline and improve the success rate of the “translational” process, the LIBH provides the following services:

  • LIBH staff and industry advisors will be available to guide faculty innovators in all aspects of the commercialization process.
  • Commercialization Boot Camp will provide a “hands on” workshop for faculty and post-docs interested in taking an active role in commercializing their innovations.
  • A Mentor Network will provide teams of advisors to guide faculty, post-docs and graduate students involved in start-up ventures.
  • The Fundamentals of the Bioscience Industry program will provide comprehensive training to graduate students and post-docs interested in the commercialization process and expanded career paths.
  • Experienced Bioentrepreneurs-in-Residence (BEIR) will develop commercialization strategies in collaboration with faculty innovators, with the objective of licensing technology for new company formation.
  • Access to a network of professional service providers and investors.

Commercialization Skills Development Resources

Educating faculty, post-docs, and graduate students about entrepreneurship and commercialization in the life sciences is an important goal of the Long Island Bioscience Hub. We have developed a curated resource library that provides videos on target topics important to those learning the ropes of the commercialization process. View the library here. 

Technology Development Resources

The REACH initiative represents a network of commercialization Hubs (UofL-ExCITE,MN-REACH, and LIBH) that can facilitate access to specialized facilities and expertise to advance development of academic-based technologies toward commercial goals. Access to these facilities and expertise is coordinated through the individual Hubs on a case by case basis. Click here for a list of specialized facilities and resources.